



An die interessierte Partei / To whom it may concern

Dr. Stefan Dreiheller
Quality Unit / Regulatory Affairs

Date of issue: 10.12.2019
Page 1/1
Doc.-No. EIP-0020
Revision 6

Melamine

FDA Guidance for Industry: Pharmaceutical Components at Risk for Melamine Contamination

MEGGLE products:

- Lactose Monohydrate Ph. Eur. / USP-NF / JP: CapsuLac[®] 60, FlowLac[®] 90, FlowLac[®] 100, GranuLac[®] 70, GranuLac[®] 140, GranuLac[®] 200, GranuLac[®] 230, PrismaLac[®] 40, SacheLac[®] 80, SorboLac[®] 400, SpheroLac[®] 100, Tablettose[®] 70, Tablettose[®] 80, Tablettose[®] 100
- Lactose Monohydrate USP-NF / Ph. Eur. / JP: InhaLac[®] 70, InhaLac[®] 120, InhaLac[®] 140, InhaLac[®] 150, InhaLac[®] 160, InhaLac[®] 230, InhaLac[®] 250, InhaLac[®] 251, InhaLac[®] 400, InhaLac[®] 500, Lactose monohydrate Low Endotoxin
- Anhydrous Lactose USP-NF / Ph. Eur. / JP: DuraLac[®] H
- Co-processed excipients: Cellactose[®] 80, CombiLac[®], MicroceLac[®] 100, RetaLac[®], StarLac[®]

The products are or contain lactose.

A monitoring program for melamine and cyanuric acid is implemented.

Testing is performed by an independent laboratory using the following method:

Liquid Chromatography/Tandem Mass Spectrometry (LC-MS-MS).

Detection limit melamine: 0.05 mg/kg. Detection limit cyanuric acid: 0.5 mg/kg.

Results show that melamine and cyanuric acid are not detectable in raw material whey.

Lactose Monohydrate Ph. Eur. / USP-NF / JP and Anhydrous Lactose Monohydrate USP-NF / Ph. Eur. / JP has a nitrogen content typically below 0,008%, and is therefore not covered by the definition for an "at-risk component" as referenced in footnote 3 of the FDA Guidance for Industry.

Freundliche Grüße / Best regards

Molkerei MEGGLE Wasserburg GmbH & Co. KG


Dr. Stefan Dreiheller